Sign In
Buy FHTX
$4.53
-0.210 (-4.43%)
At Close: Jul 31, 2026
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
11:05am, Friday, 09'th Feb 2024
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
01:31pm, Tuesday, 26'th Dec 2023
Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%
11:17am, Monday, 11'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is quest
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
07:00am, Thursday, 02'nd Nov 2023
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics: Ifs, Buts, And Clinical Holds
05:08pm, Wednesday, 16'th Aug 2023
Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology, called "gene traffic control," aims to regulate
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
09:47am, Friday, 04'th Aug 2023
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.66 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?
05:44am, Monday, 10'th Jul 2023
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
09:54am, Monday, 08'th May 2023
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.65 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
06:05am, Thursday, 27'th Apr 2023
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
04:05pm, Tuesday, 25'th Apr 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
07:20am, Monday, 24'th Apr 2023
Foghorn Therapeutics Inc.'s stock FHTX slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partial hold on a cancer trial. The company is pausing e
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
09:53am, Thursday, 09'th Mar 2023
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
